Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Nat Med
    April 2024
  1. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
    >> Share

  2. ARNOLD C
    'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
    Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024.
    >> Share

  3. YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al
    Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
    Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894.
    >> Share


  4. Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    >> Share

    March 2024
  5. O'LEARY K
    Going the extra mile to increase vaccine uptake.
    Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
    >> Share

  6. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
    >> Share

  7. XU H, Zou K, Dent J, Wiens KE, et al
    Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
    >> Share

    February 2024
  8. PERETTI-WATEL P, Verger P, Ward JK
    To understand mRNA vaccine hesitancy, stop calling the public anti-science.
    Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
    >> Share

    January 2024
  9. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    >> Share

  10. TAYLOR TE, Osier F
    Integrating vaccines and monoclonal antibodies into malaria prevention.
    Nat Med. 2024 Jan 10. doi: 10.1038/s41591-023-02745.
    >> Share

  11. PANT S, Wainberg ZA, Weekes CD, Furqan M, et al
    Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02760.
    >> Share

    December 2023
  12. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Dec 22. doi: 10.1038/s41591-023-02772.
    >> Share

  13. BARNABAS RV, Brown ER, Onono MA, Bukusi EA, et al
    Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
    Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02658.
    >> Share

    November 2023
  14. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Nov 27. doi: 10.1038/s41591-023-02670.
    >> Share

  15. O'LEARY K
    A new, affordable HPV vaccine.
    Nat Med. 2023 Nov 13. doi: 10.1038/d41591-023-00095.
    >> Share

  16. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
    Dynamics and durability of HIV-1 neutralization are determined by viral replication.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
    >> Share

  17. CHEHRAZI-RAFFLE A, Budde LE, Pal SK
    Boosting CAR T cells with anti-tumor mRNA vaccines.
    Nat Med. 2023 Nov 6. doi: 10.1038/s41591-023-02623.
    >> Share

    October 2023
  18. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Oct 24. doi: 10.1038/s41591-023-02648.
    >> Share

  19. MACKENSEN A, Haanen JBAG, Koenecke C, Alsdorf W, et al
    CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
    Nat Med. 2023 Oct 23. doi: 10.1038/s41591-023-02612.
    >> Share

    September 2023
  20. GRASSL N, Poschke I, Lindner K, Bunse L, et al
    A H3K27M-targeted vaccine in adults with diffuse midline glioma.
    Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555.
    >> Share

    August 2023
  21. CHALKIAS S, Whatley JL, Eder F, Essink B, et al
    Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Nat Med. 2023 Aug 31. doi: 10.1038/s41591-023-02517.
    >> Share

  22. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    >> Share

  23. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    >> Share

  24. JOHNSON B
    GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials.
    Nat Med. 2023 Aug 7. doi: 10.1038/d41591-023-00069.
    >> Share

    July 2023
  25. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.
    >> Share

  26. BARNES E, Goodyear CS, Willicombe M, Gaskell C, et al
    SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02414.
    >> Share

  27. BERKLEY S
    The poorest and most vulnerable communities should be the first to be vaccinated.
    Nat Med. 2023;29:1596.
    >> Share

    June 2023

  28. Precision medicine meets cancer vaccines.
    Nat Med. 2023;29:1287.
    >> Share

    May 2023
  29. VAN DER KLAAUW AA, Horner EC, Pereyra-Gerber P, Agrawal U, et al
    Accelerated waning of the humoral response to COVID-19 vaccines in obesity.
    Nat Med. 2023 May 11. doi: 10.1038/s41591-023-02343.
    >> Share

    March 2023
  30. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Author Correction: Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2023 Mar 27:1. doi: 10.1038/s41591-023-02303.
    >> Share

  31. STAMM TA, Partheymuller J, Mosor E, Ritschl V, et al
    Determinants of COVID-19 vaccine fatigue.
    Nat Med. 2023 Mar 27. doi: 10.1038/s41591-023-02282.
    >> Share

  32. LIPSCHUETZ M, Guedalia J, Cohen SM, Sompolinsky Y, et al
    Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.
    Nat Med. 2023 Mar 23. doi: 10.1038/s41591-023-02270.
    >> Share

  33. KHOURY DS, Docken SS, Subbarao K, Kent SJ, et al
    Predicting the efficacy of variant-modified COVID-19 vaccine boosters.
    Nat Med. 2023 Mar 2. doi: 10.1038/s41591-023-02228.
    >> Share

    February 2023
  34. GRANT R, Sacks JA, Abraham P, Chunsuttiwat S, et al
    When to update COVID-19 vaccine composition.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02220.
    >> Share

  35. CARVALHO T
    mRNA vaccine effective against RSV respiratory disease.
    Nat Med. 2023 Feb 15. doi: 10.1038/d41591-023-00017.
    >> Share

    January 2023
  36. SAGY YW, Zucker R, Hammerman A, Markovits H, et al
    Real-world effectiveness of a single dose of mpox vaccine in males.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02229.
    >> Share

  37. WANG G, Yao Y, Wang Y, Gong J, et al
    Determinants of COVID-19 vaccination status and hesitancy among older adults in China.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02241.
    >> Share

  38. O'LEARY K
    Cash rewards for vaccination.
    Nat Med. 2023 Jan 26. doi: 10.1038/d41591-023-00011.
    >> Share

  39. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Jan 18. doi: 10.1038/s41591-023-02219.
    >> Share

  40. LAZARUS JV, Wyka K, White TM, Picchio CA, et al
    A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
    Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02185.
    >> Share

  41. OGONGO P, Ernst JD
    Finding antigens for TB vaccines: the good, the bad and the useless.
    Nat Med. 2023 Jan 5. doi: 10.1038/s41591-022-02123.
    >> Share

    December 2022
  42. KURHADE C, Zou J, Xia H, Liu M, et al
    Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster.
    Nat Med. 2022 Dec 6. doi: 10.1038/s41591-022-02162.
    >> Share

  43. O'LEARY K
    The next generation of COVID-19 vaccines.
    Nat Med. 2022;28:2450.
    >> Share

    November 2022
  44. O'LEARY K
    A universal flu vaccine on the horizon.
    Nat Med. 2022 Nov 30. doi: 10.1038/d41591-022-00113.
    >> Share


  45. Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.
    Nat Med. 2022 Nov 4. pii: 10.1038/s41591-022-02065.
    >> Share

  46. CARVALHO T
    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.
    >> Share

    October 2022
  47. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    >> Share

  48. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    >> Share

  49. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    >> Share

  50. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    >> Share

  51. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    >> Share

  52. BHATTACHARYA D, Victora GD
    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.
    >> Share

  53. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    >> Share

    September 2022
  54. CARVALHO T
    mRNA vaccines boost BioNTech's CAR T cell therapy.
    Nat Med. 2022 Sep 1. pii: 10.1038/d41591-022-00091.
    >> Share

    August 2022
  55. PALMER CD, Rappaport AR, Davis MJ, Hart MG, et al
    Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2022;28:1619-1629.
    >> Share

    July 2022
  56. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    >> Share

  57. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    >> Share

    June 2022
  58. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    >> Share

  59. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    >> Share

    May 2022
  60. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    >> Share

  61. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    >> Share

  62. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    >> Share

  63. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    >> Share

    April 2022
  64. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    >> Share

  65. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    >> Share

  66. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    >> Share

  67. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    >> Share

    March 2022
  68. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    >> Share

  69. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    >> Share

  70. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    >> Share

  71. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    >> Share

  72. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    >> Share

    February 2022
  73. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    >> Share

  74. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    >> Share

  75. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    >> Share

  76. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    >> Share

  77. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    >> Share

  78. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    >> Share

  79. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    >> Share

  80. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    >> Share

    January 2022
  81. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    >> Share

  82. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    >> Share

  83. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    >> Share

  84. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    >> Share

  85. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    >> Share

  86. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    >> Share

  87. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    >> Share

  88. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    >> Share

    December 2021
  89. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    >> Share

  90. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    >> Share


  91. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    >> Share

  92. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    >> Share

  93. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    >> Share

  94. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    >> Share

  95. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    >> Share

  96. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    >> Share

  97. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    >> Share

  98. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    >> Share

  99. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    >> Share

    November 2021
  100. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
    >> Share

  101. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
    >> Share

  102. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
    >> Share

  103. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
    >> Share

  104. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    >> Share

  105. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    >> Share

  106. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    >> Share

    October 2021
  107. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    >> Share

  108. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    >> Share

  109. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
    >> Share

    September 2021
  110. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
    >> Share

  111. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    >> Share

  112. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016